This topic contains 1 reply, has 2 voices, and was last updated by Virginia Seery November 3, 2017 at 2:07 am.

Viewing 2 posts - 1 through 2 (of 2 total)
  • Author
    Posts
  • #4263

    Can you please provide commentary about the new data on use of BRAF/MEK inhibitors in the adjvuvant setting? Do you expect the side effects to be similar to what is seen in the metastatic setting?

    #4276
    Expert Nurse
    Virginia Seery
    Virginia Seery

    Hi Lisa,
    Krista Rubin gave an excellent overview of targeted therapy in the adjuvant setting (from the COMBI-AD Phase 3 trial) in the immunotherapy section above. In terms of practice change, this would call for BRAF testing in all Stage III patients which is not necessarily the standard approach for all practices. This is a very exciting time in melanoma!

Viewing 2 posts - 1 through 2 (of 2 total)

You must be logged in to reply to this topic.